GSK: Covid-19 vaccine agreements with Canada
(CercleFinance.com) - Sanofi and GSK announce that they have signed agreements with the government of Canada to supply up to 72 million doses of their adjuvanted Covid-19 vaccine, starting in 2021.
This vaccine is currently being developed.
Both companies operate vaccine manufacturing facilities in Canada that are contributing to the development of a vaccine against Covid-19, supported by their respective global industrial networks.
Sanofi and GSK launched a Phase I/II trial on 3 September. They expect to obtain the first results in early December 2020 and to be in a position to launch a pivotal Phase III trial before the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This vaccine is currently being developed.
Both companies operate vaccine manufacturing facilities in Canada that are contributing to the development of a vaccine against Covid-19, supported by their respective global industrial networks.
Sanofi and GSK launched a Phase I/II trial on 3 September. They expect to obtain the first results in early December 2020 and to be in a position to launch a pivotal Phase III trial before the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.